

## REMARKS

Claims 82-118 are pending.

Formula (A) at page 6 of the specification, respectively, have been amended to correct the number of R<sup>6</sup> groups. As described in the specification, three of the Qs may be a nitrogen atom. Therefore, the minimum number of R<sup>6</sup> groups is 1 (when 3 Qs are nitrogen atoms) and the maximum number of R<sup>6</sup> groups is 4 (when none of the Qs are nitrogen atoms). Formula (A) has been amended to correctly show 1-4 R<sup>6</sup> groups. The bottom of page 7 and page 15 have been amended to correct a typographical error. As shown in formula (A), there are no R<sup>5</sup> groups substituting the Qs in the ring. In addition, a revised Abstract has been submitted to make the corresponding change to formula (A).

Claim 82 has been amended to specify 3 R<sup>6</sup> groups in formula (A) in view of the remarks above, i.e., because one Q is a nitrogen atom. The definition of Q has also been amended to reflect the changes made to the specification discussed above.

In addition, Claim 116 has been amended to specify a P2Y2 receptor agonist. That amendment is supported by the specification at page 20, line 10.

No new matter is believed to have been added to this application by the amendments submitted above.


Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)



---

James J. Kelly, Ph.D.  
Attorney of Record  
Registration No. 41,504

JK\la